Identifying robust preclinical models for lymphoma is essential for the development of new therapies targeting this disease. Patient Derived Xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity providing an accurate approach to predicting an agent’s efficacy prior to entering the clinic. The CrownBio lymphoma PDX collection consists of many models, including both primary and metastatic models. Learn more about this collection in the following publication: More
-Simultaneous Inhibition of PI3Kd and PI3Ka Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-kB and AKT.pdf
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.